ReviewFrontiers in pharmacology2021
The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer's Disease.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Effectiveness and safety of ginkgo biloba preparations in the treatment of Alzheimer's disease: A systematic review and meta-analysis.Frontiers in aging neuroscience · 2023Pooled it
- Yucca filamentosa extract therapeutic potential against neuro-inflammation and demyelination through modulation of eicosanoids.Inflammopharmacology · 2026Article
- Ficus deltoidea Preserves Hippocampal Neuronal Integrity and Redox Balance in Oxidative Stress-Driven Alzheimer's Disease-Like Rat Model.Molecular neurobiology · 2026Article
- Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings.Natural products and bioprospecting · 2026Review
- Review
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Ginkgetin Alleviates Doxorubicin-Induced Heart Failure by Regulating Mitochondrial Dysfunction Through the AMPK/Sirt1/NF-κB Signaling Pathway.Balkan medical journal · 2026Article
- ZPT01, a herbal formula of Zingiberis Rhizoma, Paeoniae Radix and Tribuli Fructus, protects dopaminergic neurons and suppresses neuroinflammation in a Parkinson's disease model.Molecular biology reports · 2026Article
- Review
- Adjunctive EGb 761 treatment in patients with Parkinson's disease: a case series.Frontiers in aging neuroscience · 2026Article
- Ginkgolide as a Promising Multi-Target Therapeutic for Alzheimer's Disease: Targeting ApoE4 and Beyond.Current pharmaceutical design · 2026Article
- Unveiling the Pharmacological Effects ofCentral nervous system agents in medicinal chemistry · 2026Review
- Advances in Bioactive Compounds from Plants and Their Applications in Alzheimer's Disease.Biomolecules · 2025Review
- RoastedAntioxidants (Basel, Switzerland) · 2025Article
- Interactions of Extracts from Selected Plant Materials Supporting the Treatment of Alzheimer's Disease with Free Radicals-EPR and UV-Vis Studies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Ginkgo biloba L. leaf extract (EGb 761) alleviates reserpine-induced depression-like symptoms in aged rats by enhancing serotonin/norepinephrine levels and reducing oxidative/nitrosative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Hepatoprotective mechanisms of ginkgo-Biloba and dandelion extracts: antioxidant activity and modulation of TNF-α and P53 pathways in Thioacetamide-induced liver injury.Toxicology research · 2025Article
- Trojan Horse Delivery Strategies of Natural Medicine Monomers: Challenges and Limitations in Improving Brain Targeting.Pharmaceutics · 2025Review
- Potential therapeutic effects of Ebixa,Frontiers in neuroscience · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease, a neurodegenerative disease, is one of the most common causes of dementia if elderly people worldwide. Alzheimer's disease leads to the alienation of individuals and their exclusion from social and professional life. It is characterized mainly by the degradation of memory and disorientation, which occurs as a result of the loss of neuronal structure and function in different brain areas. In recent years, more and more attention has been paid to use in the treatment of natural bioactive compounds that will be effective in neurodegenerative diseases, including Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.